WASHINGTON — President Trump announced a plan to impose 100 percent tariffs on all imported generic drugs beginning Jan. 1, 2028. The policy aims to force pharmaceutical manufacturing back into the United States, targeting countries like India and China, which currently supply more than 70 percent of U.S. generic medications.
The move marks a victory for U.S.-based generic drug producers, including Teva Pharmaceutical Industries and Viatris Inc. which maintain some domestic production. These firms have lobbied Congress for protectionist policies and incentives to onshore manufacturing, citing national security and supply chain resilience. In 2025, the generic pharmaceutical industry spent $12.4 million on lobbying, focusing on committees with jurisdiction over trade and healthcare, according to OpenSecrets data.
Consumers will absorb the direct financial hit. Generic drugs account for 90 percent of all prescriptions filled in the United States and typically cost 80 percent to 85 percent less than brand-name drugs. A 100 percent tariff would effectively double the cost of imported generics, driving sharp price increases at pharmacies. The burden will fall hardest on lower-income households and patients with chronic conditions who depend on affordable medications.
The administration frames the policy as essential to reducing reliance on foreign supply chains, a vulnerability exposed during the COVID-19 pandemic. But shifting pharmaceutical production to the United States by 2028 presents a logistical and financial challenge for manufacturers, requiring billions in new capital investment and years of development. The supply chain runs deep: manufacturers depend on global networks for active pharmaceutical ingredients as well as finished products.
Critics argue the policy prioritizes profits for a handful of domestic manufacturers over broad consumer access to affordable medicine. They also warn of inflationary pressure and potential drug shortages if domestic capacity cannot meet demand. Federal programs like Medicare and Medicaid, which cover millions of prescriptions, would face substantial added costs.
